Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $1.29B |
| Gross Profit (TTM) | $311.76M |
| EBITDA | $109.51M |
| Operating Margin | 10.80% |
| Return on Equity | 14.90% |
| Return on Assets | 9.12% |
| Revenue/Share (TTM) | $15.30 |
| Book Value | $5.66 |
| Price-to-Book | 5.39 |
| Price-to-Sales (TTM) | 1.86 |
| EV/Revenue | 1.676 |
| EV/EBITDA | 21.28 |
| Quarterly Earnings Growth (YoY) | 70.60% |
| Quarterly Revenue Growth (YoY) | 1.40% |
| Shares Outstanding | $78.33M |
| Float | $71.61M |
| % Insiders | 1.94% |
| % Institutions | 112.05% |
Volatility is currently contracting
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time.
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors with an interest in Medical Services stocks have likely encountered both Progyny (PGNY) and Alignment Healthcare (ALHC). But which of these two stocks is more attractive to value investors?
